Biogen Collaborates with Vir Biotechnology to Develop Antibodies Against COVID-19

 Biogen Collaborates with Vir Biotechnology to Develop Antibodies Against COVID-19

Biogen Collaborates with Vir Biotechnology to Develop Antibodies AgBiogen Collaborates with Vir Biotechnology to Develop Antibodies Against COVID-19ainst COVID-19

Shots:

  • Biogen has signed a letter of intent with Vir to develop & manufacture mAb targeting COVID-1 and have started working together due to the urgency of the crisis while a development & manufacturing agreement is being negotiated
  • Following the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities, advancing the development of Vir’s Abs
  • Vir has identified several mAb targeting SARS-CoV-2, which were isolated from patients who had survived a SARS infection. The company is also evaluating its Abs as an effective treatment/ or prophylaxis against SARS-CoV-2

Click here ­to­ read full press release/ article | Ref: GlobeNewswire  | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post